FDA Grants Priority Review for Atacicept IgAN Treatment
Vera Therapeutics receives FDA Priority Review for atacicept, a potential first-in-class treatment for IgA nephropathy with a decision expected by July 2026.
/ 1662 items
#XY↓
Major Biotech Upgrades and Coverage Initiations: Regeneron, Erasca, Protara, Design Therapeutics, Oric
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
Ascentage Pharma's New Cancer Drug Gets FDA Green Light for Clinical Trials
Ascentage Pharma receives FDA clearance for APG-3288, an innovative BTK protein degrader designed to treat resistant blood cancers through a novel degradation approach.
Monte Rosa's MRT-8102 Reduces Heart Disease Risk by 85%
Monte Rosa Therapeutics (GLUE) announces positive Phase 1 results for MRT-8102, showing 85% reduction in inflammation markers and potential for preventing cardiovascular disease.
Compass Pathways Advances PTSD Treatment and Prepares for Depression Launch
Compass Pathways receives FDA approval to begin late-stage PTSD trials with COMP360 psilocybin treatment while preparing for potential 2026 launch for treatment-resistant depression.
GSK and Ionis Announce Major Win Against Hepatitis B in Landmark Trials
GSK and Ionis announce breakthrough results for bepirovirsen, a potential first-in-class treatment offering functional cure for chronic hepatitis B in just six months.